The Brain, Mind, and Pain Patient-Centred Innovation Grant has been initiated by Pain Alliance Europe and supported by Grünenthal Group with the main aim of encouraging patient-centred innovation having, as a result, the improvement of the living conditions of pain patients.

The Brain, Mind, and Pain Patient-Centred Innovation Grant aims to create an environment where patient centricity is the basis for future initiatives. This will implicitly contribute towards creating a sense of innovation, with a direct impact on patients’ needs, and towards increasing awareness of chronic pain conditions and neurological disorders.

The biennial grant provided by Grünenthal addresses individual applicants as well as different organisations’ initiatives and partnerships, invited to present their innovation projects or ideas with direct impact on brain, mind, and pain patients’ quality of life.

Patients’ organisations are given a central role in outlining this great initiative in order to ensure the “patient-centred” orientation of the grant and are sustained by scientific consultants from partner organisations.

The Jury composed of patients representatives led by Pain Alliance Europe perform the selection of the Brain, Mind, and Pain Patient-Centred Innovation Grant winning candidate(s).



About Pain Alliance Europe

Pain Alliance Europe is a non-governmental umbrella organization of national associations committed to improving the quality of life of people with chronic pain in Europe.

For PAE, quality of life for a chronic pain patient means giving the patient the right to choose the best possible solutions and the support to live their life according to their possibilities and wishes. It aims to increase awareness of chronic pain, to promote European policy on chronic pain and to reduce the impact of chronic pain on the European society at all levels. 

More information about PAE is available at

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout, and inflammation. Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.

Grünenthal is an independent, family-owned company headquartered in Aachen, Germany. We are present in 32 countries with affiliates in Europe, Latin America, and the US. Our products are sold in more than 155 countries and approx. 5,500 employees are working for the Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of approx. € 1.4 bn.

More information: